Cytokinetics - Updated FOREST-HCM Data
Additional 48-week data from FOREST-HCM presented
What timing! After I published my CYTK summary (see below), the company released updated data from the FOREST-HCM study!
Cytokinetics Summary
Investment Summary Cytokinetics is essentially a bet on aficamten. It has succeeded in a pivotal phase III that could potentially lead to an approval in 2025 for obstructive HCM. Additional trials are ongoing in non-obstructive and obstructive HCM that will likely drive uptake and additional indications.
As background, FOREST-HCM is aficamten’s open label extension study that has thus far recruited 213 patients. Initial data on 17 patients were shared previously; the new analysis provides data on 46 patients with 48 weeks of follow up (press release).
The new data was presented at the 73rd Annual American College of Cardiology (ACC) Scientific Session. Key highlights from the poster are below.
Keep reading with a 7-day free trial
Subscribe to Ninja Reports to keep reading this post and get 7 days of free access to the full post archives.